Search

Researchers have discovered that cancer cells may hijack an immune response to spread from a primary tumor to distant organs.

… Wednesday, January 17, 2018 Summary A new finding suggests that a genetic mistake in cancer cells known as chromosomal instability creates an inflammatory state within the cells. The cancer cells take advantage of this condition by hijacking pathways used by immune cells to migrate. This enables these

Michael A. Foley, PhD, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute, Inc., a pioneering collaboration of Weill Cornell Medical College, The Rockefeller University and Memorial Sloan Kettering Cancer Center.

… Thursday, December 5, 2013 Michael A. Foley, PhD, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute , Inc. (Tri-I TDI), a pioneering collaboration of Weill Cornell Medical College, The Rockefeller University and Memorial Sloan Kettering Cancer Center that is designed to

The FDA has approved the first-ever treatment developed for low-grade serous ovarian cancer, a rare type of ovarian cancer.

… Monday, May 12, 2025 The first drug for a rare and difficult-to-treat type of  ovarian cancer has been granted  accelerated approval by the Food and Drug Administration (FDA). The treatment, called avutometinib plus defactinib (Avmapki TM Fakzynja TM Co-pack), was developed to treat low-grade serous

Learn about how The Society of Memorial Sloan Kettering is supporting precision medicine at MSK Kids.

… Wednesday, April 1, 2020 On February 5, The Society of Memorial Sloan Kettering hosted its seventh annual Winter Lunch to support its Precision Medicine for MSK Kids initiative. More than 275 guests attended this year’s event, which was sponsored by Net-a-Porter for the fifth consecutive year, at the

Mutations in a gene called FOXA1 are responsible for a distinct class of prostate cancer tumors, MSK researchers have found.

… Wednesday, June 26, 2019 Summary Researchers at Memorial Sloan Kettering have identified molecular changes in a protein that promote a distinct type of prostate cancer. The findings suggest that this protein could be a good drug target for men with this form of the disease. Prostate cancer is not one

Antibody-drug conjugates and checkpoint inhibitors show promise as new therapies for bladder cancer.

… Monday, September 12, 2022 Promising new drugs have begun to transform the treatment of bladder (or urothelial) cancer, the sixth most common form of the disease in the U.S., and the fourth most common in men. In particular, two drug classes, antibody-drug conjugates (ADCs) and checkpoint inhibitors,

An MSK clinical trial is helping Gail Goode overcome multiple myeloma and sheds new light on how cancer affects people of diverse ethnic backgrounds.

… Tuesday, September 3, 2024 There is an urgent need to recruit more diverse patients into cancer clinical trials . One reason it’s so important is that researchers are learning that certain types of cancer occur more frequently in people with certain ancestries. For example:   African — people of African

Un ensayo clínico de MSK está ayudando a Gail Goode a superar el mieloma múltiple y arroja nueva luz sobre cómo el cáncer afecta a personas de diversos orígenes étnicos.

… Tuesday, September 3, 2024 Existe una necesidad urgente de reclutar a pacientes más diversos en los ensayos clínicos de cáncer . Una de las razones por las que es tan importante es que los investigadores están descubriendo que ciertos tipos de cáncer ocurren con mayor frecuencia en personas de determinadas

Internationally recognized cancer biologist Joan Massagué has been named Director of the Sloan Kettering Institute. He was previously Chair of the Cancer Biology and Genetics Program at Memorial Sloan Kettering.

… Monday, November 25, 2013 Summary Internationally recognized cancer biologist Joan Massagué has been named Director of the Sloan Kettering Institute. He was previously Chair of the Cancer Biology and Genetics Program at Memorial Sloan Kettering. Renowned cancer biologist Joan Massagué has been named

Experts from MSK shared their work in more than 40 presentations and poster sessions at the 2023 meeting of ASTRO, the American Society for Therapeutic Radiology and Oncology.

… Wednesday, October 4, 2023 Researchers from Memorial Sloan Kettering Cancer Center (MSK) were recognized for their achievements at the 2023 meeting of ASTRO, the American Society for Therapeutic Radiology and Oncology. Teams reported new findings about radiation-induced secondary cancers, a new guidance